Clinical implications of aspirin resistance

Summary

Aspirin reduces major atherothrombotic events across a wide spectrum of patients with atherosclerotic disease. The occurrence of ischemic events despite of aspirin treatment is a failure of therapy, often denoted ‘clinical aspirin resistance’. This is distinguished from laboratory assays showing an insufficient inhibition of platelet function, which indicate ‘laboratory aspirin resistance’. Laboratory aspirin resistance has been reported in up to 60% of patients after stroke or peripheral arterial disease, up to 70% in stable coronary heart disease and even up to 80% in acute myocardial infarction. However, this data must be interpreted carefully because of small sample sizes and potential confounding factors such as compliance, co-morbidities and large differences between the laboratory methods used for detection. During the past years, evidence has accumulated that laboratory aspirin resistance is associated with an increased incidence of major atherothrombotic events, with an up to 13-fold increased risk of events in patients with cardiovascular disease. Thus, an individualized antiplatelet therapy will have to consider the possibility of aspirin resistance, and the identification of aspirin non-responders may improve antiplatelet therapy in future. Whether an increased dose of aspirin or another antiplatelet drug (e.g. clopidogrel) instead or in addition to aspirin should be given is unclear. Prospective trials are underway which address this issue. This review gives an overview on the various clinical studies that have investigated the prevalence and clinical importance of laboratory aspirin resistance. Moreover, therapeutic options, as well as future perspectives are discussed.

Keywords

Aspirin resistance - atherosclerosis - platelet function - prevalence - clinical outcome

• References

• 1 Roth GJ, Stanford N, Majerus PW. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci USA 1975; 72: 3073-3076.
• 2 Schrör K. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Semin Thromb Hemost 1997; 23: 349-356.
• 3 Patrono C, Patrignani P, Garcia-Rodriguez LA. Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. J Clin Invest 2001; 108: 7-13.
• 4 Mehta P. Aspirin in the prophylaxis of coronary artery disease. Curr Opin Cardiol 2002; 17: 552-558.
• 5 Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 2006; 116: 4-15.
• 6 Antithrombotic Trialist´s Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002; 324: 71-86.
• 7 Cattaneo M. Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection. J Thromb Haemost 2007; 05 (Suppl. 01) 230-237.
• 8 Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet 2006; 367: 606-617.
• 9 Hanjis C, Frishman WH, Lerner RG. Aspirin resistance: mechanisms and clinical implications. Cardiol Rev 2006; 14: 18-25.
• 10 Schroeder WS, Ghobrial L, Gandhi PJ. Possible mechanisms of drug-induced aspirin and clopidogrel resistance. J Thromb Thrombolysis 2006; 22: 139-150.
• 11 Serebruany VL, Hanley Jr. DF, Atar D. et al. Noncompliance in antiplatelet trials: the AGATE trial perspective. Stroke 2004; 35: e143.
• 12 Cox D, Maree AO, Dooley M. et al. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. Stroke 2006; 37: 2153-2158.
• 13 De Gaetano G, Cerletti C, Dejana E. et al. Pharmacology of platelet inhibition in humans: implications of the salicylate-aspirin interaction. Circulation 1985; 72: 1185-1193.
• 14 Catella-Lawson F, Reilly MP, Kapoor SC. et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345: 1809-1817.
• 15 Capone ML, Sciulli MG, Tacconelli S. et al. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol 2005; 45: 1295-1301.
• 16 Hohlfeld T, Zimmermann N, Weber AA. et al. Pyrazolinone analgesics prevent the antiplatelet effect of aspirin and preserve human platelet thromboxane synthesis. J Thromb Haemost 2008; 06: 166-173.
• 17 Crescente M, Cerletti C, De Gaetano G. Gallic acid, a dietary polyphenolic component, blunts the inhibition of platelet COX-1 by aspirin: preliminary in-vitro findings. Thromb Haemost 2007; 97: 1054-1056.
• 18 Larsson PT, Wallen NH, Hjemdahl P. Norepinephrine-induced human platelet activation in vivo is only partly counteracted by aspirin. Circulation 1994; 89: 1951-1957.
• 19 Hurlen M, Seljeflot I, Arnesen H. Increased platelet aggregability during exercise in patients with previous myocardial infarction. Lack of inhibition by aspirin. Thromb Res 2000; 99: 487-494.
• 20 Guthikonda S, Lev EI, Patel R. et al. Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin. J Thromb Haemost 2007; 05: 490-496.
• 21 Rocca B, Secchiero P, Ciabattoni G. et al. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci USA 2002; 99: 7634-7639.
• 22 Censarek P, Freidel K, Udelhoven M. et al. Cyclooxygenase COX-2a, a novel COX-2 mRNA variant, in platelets from patients after coronary artery bypass grafting. Thromb Haemost 2004; 92: 925-928.
• 23 Kawasaki T, Ozeki Y, Igawa T. et al. Increased platelet sensitivity to collagen in individuals resistant to low-dose aspirin. Stroke 2000; 31: 591-595.
• 24 Macchi L, Christiaens L, Brabant S. et al. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res 2002; 107: 45-49.
• 25 Marin F, Roldan V, Gonzalez-Conejero R. et al. The pharmacogenetics of antiplatelet drugs. Curr Opin Investig Drugs 2007; 08: 213-218.
• 26 Toth O, Calatzis A, Penz S. et al. Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood. Thromb Haemost 2006; 96: 781-788.
• 27 Ivandic BT, Giannitsis E, Schlick P. et al. Determination of aspirin responsiveness by use of whole blood platelet aggregometry. Clin Chem 2007; 53: 614-619.
• 28 Malinin AI, Atar D, Callahan KP. et al. Effect of a single dose aspirin on platelets in humans with multiple risk factors for coronary artery disease. Eur J Pharmacol 2003; 462: 139-143.
• 29 Gum PA, Kottke-Marchant K, Poggio ED. et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001; 88: 230-235.
• 30 Zimmermann N, Wenk A, Kim U. et al. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation 2003; 108: 542-547.
• 31 Hovens MM, Snoep JD, Eikenboom JC. et al. Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. Am Heart J 2007; 153: 175-181.
• 32 Krasopoulos G, Brister SJ, Beattie WS. et al. Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis. Br Med J 2008; 336: 195-198.
• 33 Snoep JD, Hovens MC, Eikenboom CJ. et al. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events. Arch Intern Med 2007; 167: 1593-1599.
• 34 Crescente M, Di Castelnuovo A, Iacoviello L. et al. Response variability to aspirin as assessed by the platelet function analyzer (PFA)-100. A systematic review. Thromb Haemost 2008; 99: 14-26.
• 35 Reny JL, De Moerloose P, Dauzat M. et al. Use of the PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis. J Thromb Haemost 2008; 06: 444-450.
• 36 Andersen K, Hurlen M, Arnesen H. et al. Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res 2002; 108: 37-42.
• 37 Gum PA, Kottke-Marchant K, Welsh PA. et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 41: 961-965.
• 38 Cotter G, Shemesh E, Zehavi M. et al. Lack of aspirin effect: aspirin resistance or resistance to taking aspirin?. Am Heart J 2004; 147: 293-300.
• 39 Stejskal D, Vaclavik J, Lacnak B. et al. Aspirin resistance measured by cationic propyl gallate platelet aggregometry and recurrent cardiovascular events during 4 years of follow-up. Eur J Intern Med 2006; 17: 349-354.
• 40 Pamukcu B, Oflaz H, Oncul A. et al. The role of aspirin resistance on outcome in patients with acute coronary syndrome and the effect of clopidogrel therapy in the prevention of major cardiovascular events. J Thromb Thrombolysis 2006; 22: 103-110.
• 41 Cuisset T, Frere C, Quilici J. et al. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost 2006; 04: 542-549.
• 42 Pamukcu B, Oflaz H, Onur I. et al. Clinical relevance of aspirin resistance in patients with stable coronary artery disease: a prospective follow-up study (PROSPECTAR). Blood Coagul Fibrinolysis 2007; 18: 187-192.
• 43 Chen WH, Cheng X, Lee PY. et al. Aspirin resistance and adverse clinical events in patients with coronary artery disease. Am J Med 2007; 120: 631-635.
• 44 Valles J, Santos MT, Fuset MP. et al. Partial inhibition of platelet thromboxane A₂ synthesis by aspirin is associated with myonecrosis in patients with ST- segment elevation myocardial infarction. Am J Cardiol 2007; 99: 19-25.
• 45 Chen WH, Lee PY, Ng W. et al. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 2004; 43: 1122-1126.
• 46 Lev EI, Patel RT, Maresh KJ. et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol 2006; 47: 27-33.
• 47 Buchanan MR, Schwartz L, Bourassa M. et al. Results of the BRAT study -a pilot study investigating the possible significance of ASA nonresponsiveness on the benefits and risks of ASA on thrombosis in patients undergoing coronary artery bypass surgery. Can J Cardiol 2000; 16: 1385-1390.
• 48 Poston RS, Gu J, Brown JM. et al. Endothelial injury and acquired aspirin resistance as promoters of regional thrombin formation and early vein graft failure after coronary artery bypass grafting. J Thorac Cardiovasc Surg 2006; 131: 122-130.
• 49 Borna C, Lazarowski E, van Heusden C. et al. Resistance to aspirin is increased by ST-elevation myocardial infarction and correlates with adenosine diphosphate levels. Thromb J 2005; 03: 10.
• 50 Norgaz T, Hobikoglu G, Serdar ZA. et al. Is there a link between nickel allergy and coronary stent restenosis?. Tohoku J Exp Med 2005; 206: 243-246.
• 51 Wenaweser P, Dorffler-Melly J, Imboden K. et al. Stent thrombosis is associated with an impaired response to antiplatelet therapy. J Am Coll Cardiol 2005; 45: 1748-1752.
• 52 Pamukcu B, Oflaz H, Nisanci Y. The role of platelet glycoprotein IIIa polymorphism in the high prevalence of in vitro aspirin resistance in patients with intracoronary stent restenosis. Am Heart J 2005; 149: 675-680.
• 53 Yilmaz MB, Balbay Y, Caldir V. et al. Late saphenous vein graft occlusion in patients with coronary bypass: possible role of aspirin resistance. Thromb Res 2005; 115: 25-29.
• 54 Hobikoglu GF, Norgaz T, Aksu H. et al. High frequency of aspirin resistance in patients with acute coronary syndrome. Tohoku J Exp Med 2005; 207: 59-64.
• 55 Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb Res 1993; 71: 397-403.
• 56 Grundmann K, Jaschonek K, Kleine B. et al. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol 2003; 250: 63-66.
• 57 Ziegler S, Maca T, Alt E. et al. Monitoring of antiplatelet therapy with the PFA-100 in peripheral angioplasty patients. Platelets 2002; 13: 493-497.
• 58 Mueller MR, Salat A, Stangl P. et al. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 1997; 78: 1003-1007.
• 59 Eikelboom JW, Hirsh J, Weitz JI. et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105: 1650-1655.
• 60 Ohmori T, Yatomi Y, Nonaka T. et al. Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients. J Thromb Haemost 2006; 04: 1271-1278.
• 61 Syrbe G, Redlich H, Ludwig J. et al. Individual dosing of ASA prophylaxis by controlling platelet aggregation. Clin Appl Thromb Haemost 2001; 07: 209-213.
• 62 Helgason CM, Bolin KM, Hoff JA. et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke 1994; 25: 2331-2336.
• 63 Bornstein NM, Karepov VG, Aronovich BD. et al. Failure of aspirin treatment after stroke. Stroke 1994; 25: 275-277.
• 64 Wong S, Morel-Kopp MC, Chen Q. et al. Overcoming aspirin resistance: Increased platelet inhibition with combination aspirin and clopidogrel and high dose aspirin therapy in aspirin resistant patients with peripheral vascular disease. Thromb Haemost 2006; 95: 1042-1043.
• 65 Roller RE, Dorr A, Ulrich S. et al. Effect of aspirin treatment in patients with peripheral arterial disease monitored with the platelet function analyzer PFA-100. Blood Coagul Fibrinolysis 2002; 13: 277-281.
• 66 Gonzalez-Conejero R, Rivera J, Corral J. et al. Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure?. Stroke 2005; 36: 276-280.
• 67 Yusuf S, Zhao F, Mehta SR. et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
• 68 Steinhubl SR, Berger PB, Mann III JT. et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. J Am Med Assoc 2002; 288: 2411-2420.
• 69 Markus HS, Droste DW, Kaps M. et al. Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial. Circulation 2005; 111: 2233-2240.
• 70 Diener HC, Bogousslavsky J, Brass LM. et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004; 364: 331-337.
• 71 Bhatt DL, Fox KA, Hacke W. et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354: 1706-1717.
• 72 Bhatt DL, Flather MD, Hacke W. et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 2007; 49: 1982-1988.
• 73 Gurbel PA, Bliden KP, Hiatt BL. et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107: 2908-2913.
• 74 Geisler T, Gawaz M. Variable response to clopidogrel in patients with coronary artery disease. Semin Thromb Hemost 2007; 33: 196-202.
• 75 Forbes CD. Secondary stroke prevention with low-dose aspirin, sustained release dipyridamole alone and in combination. ESPS Investigators. European Stroke Prevention Study. Thromb Res 1998; 92: S1-S6.
• 76 De Schryver EL, Algra A, van Gijn J. Cochrane review: dipyridamole for preventing major vascular events in patients with vascular disease. Stroke 2003; 34: 2072-2080.
• 77 Michelson AD, Cattaneo M, Eikelboom JW. et al. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost 2005; 03: 1309-1311.
• 78 Pettersen AA, Seljeflot I, Abdelnoor M. et al. Unstable angina, stroke, myocardial infarction and death in aspirin non-responders. A prospective, randomized trial. The ASCET (ASpirin non-responsiveness and Clopidogrel Endpoint Trial) design. Scand Cardiovasc J 2004; 38: 353-356.
• 79 Cheng X, Chen WH, Simon DI. Aspirin resistance or variable response or both?. Am J Cardiol 2006; 98: S11-S17.